The medicines we develop and deliver to our customers help one million patients each day. With an increasing demand for our services, expertise and capabilities, comes a commitment to continuously expand our products and services. This is why we have been making unprecedented investments in our network of sites and capabilities around the world.Our investment is not just about adding capacity—it’s about enhancing capabilities across our Pharma Services business. By drawing on the collective expertise from businesses across Thermo Fisher, expanding our network of best-in-class facilities, and strengthening our workforce with exceptional talent, we provide solutions to our customers that enable them to accelerate innovation and productivity and get medicines to their patients faster. Learn more about our newly expanded capabilities below.
Thermo Fisher Investing $82.5 million on Expansion of St. Louis Manufacturing FacilityThermo Fisher is investing $82.5 million to expand operations and create 169 new jobs at its St. Louis, MO, biologic drug manufacturing facility. The expanded facility will manufacture biologic drug substance products that treat a variety of chronic health conditions including cancers and other life-threatening diseases including COVID-19. Thermo Fisher’s current commercial biologics manufacturing footprint in St. Louis is approximately 360,000 square feet and approximately 700 employees. The expansion project will include a 58,000 square foot expansion with two new manufacturing suites and the addition of new manufacturing machinery and equipment, including the new ability to provide manufacturing and production support at the 5KL processing scale as well as continued support at the 2KL processing scale.
Bioprocessing Collaboration Center (BCC)The new Bioprocessing Collaboration Center (BCC) in St. Louis, Missouri, uniquely positions Thermo Fisher to bring together industry-leading expertise in single-use technologies and biologics product development and manufacturing to deliver unmatched value to our customers. The facility is adjacent to our biologics manufacturing facility, which recently doubled production capacity with a $50M expansion. The combined expertise from our bioproduction and pharma services businesses will accelerate innovation and enhance productivity for biopharma customers, enabling them to meet the growing need for more flexible, scalable biologics development and manufacturing solutions.